- Areas of Interest
- Techniques
- Systems
- Products & Services
- Informatics
- Science & Education
- Company
- Support
Illumina provides an innovative portfolio of genomic sequencing systems, products, and services for the drug development pipeline. With solutions to inform the drug development process, you can confidently choose us as a partner from discovery through companion diagnostics development.
We are uniquely positioned to deliver products and services to support pharmaceutical development with the largest install base of next-generation sequencing (NGS) instrumentation.
Approximately 90 percent of all sequencing data produced today has been generated using Illumina technologies*. Reference and service labs are installing our instruments in increasing numbers to perform a wide variety of applications.
* Data calculations on file. Illumina, Inc. 2017
The Illumina portfolio of solutions informs various stages of the drug development process.
Click on the below to view methods and products supporting drug development.
Take a comprehensive view of the genomic variation linked to a pathway.
Whole-Exome SequencingExplore genomic variation in a more cost-effective way.
Targeted Cancer SequencingTake a deeper view to confirm genomic variation of interest with custom or fixed panels. Detect single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression with TruSight Tumor 170.
TruSight Oncology 500Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples.
Cancer RNA SequencingCharacterize expression by sequencing individual targets to the entire transcriptome.
Cancer Immunotherapy ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.
Learn how to use RNA-Seq to identify novel RNA-based drug response biomarkers.
Sequencing SystemsFind the sequencer that best fits your scale of study.
Microarray SolutionsA complete range of tools and services for every need.
Bioinformatics ToolsInformatics tools to guide you from experimental design to data interpretation and reporting.
Service ProvidersFind a service provider through our Propel program to support your genomics needs.
Take a deeper view to confirm genomic variation of interest with custom or fixed panels. Detect single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression with TruSight Tumor 170.
TruSight Oncology 500Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples.
Cancer RNA SequencingConfirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples. Also leverage RNA-Seq for the discovery and profiling of RNA-based drug response biomarkers.
Immunotherapy ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment
Find the sequencer that best fits your scale of study.
InformaticsBioinformatics tools guide you from experimental design to data interpretation and reporting.
Service ProvidersFind a service provider through our Propel program to support your genomics needs.
Take a deeper view to confirm genomic variation of interest with custom or fixed panels. Detect single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression with TruSight Tumor 170.
TruSight Oncology 500Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples.
Cancer RNA SequencingConfirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples. Also leverage RNA-Seq to discover and profile drug response RNA biomarkers.
Immunotherapy ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment
Find the sequencer that best fits your scale of study.
InformaticsBioinformatics tools guide you from experimental design to data interpretation and reporting.
Service ProvidersFind a service provider through our Propel program to support your genomics needs.
Explore our unique, multi-analyte approach to co-development.
Targeted Cancer SequencingTake a deeper view to confirm genomic variation of interest with custom or fixed panels. Detect single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression with TruSight Tumor 170.
TruSight Oncology 500Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples.
Cancer RNA SequencingConfirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples.
Immunotherapy ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.
Find the sequencer that best fits your scale of study.
Companion Diagnostic DevelopmentExplore our unique, multi-analyte approach to co-development.
High-Throughput Genotyping Research ToolsGain meaningful insights from complex populations.
InformaticsBioinformatics tools guide you from experimental design to data interpretation and reporting.
Service ProvidersFind a service provider through our Propel program to support your genomics needs.
Explore our unique, multi-analyte approach to co-development.
MiSeqDx InstrumentDiscover the first FDA-cleared next-generation sequencing system.
NextSeq550Dx InstrumentExplore the next level in diagnostic power for the clinical lab.
Gain meaningful insights from complex populations.
Service ProvidersFind a service provider through our Propel program to support your genomics needs.
An overview of exciting new fields of immunotherapy research, and how NGS helps to move them forward.
Access resources to explore NGS-based biomarker discovery and profiling.
Almac Diagnostics is using the TruSight Tumor 170 assay for comprehensive high-quality genomic content in one streamlined workflow.
Regeneron discusses their latest work and overall mission to explore new variations in genomes that can help explain disease.
Garret Hampton, EVP of Clinical Genomics at Illumina, shares his vision for how genomics might shape the future of oncology.
Read how Merck Serono uses NGS for cell line stability testing and biosafety monitoring.
The Propel Certification Program is designed to promote high data quality and best practices at fee-for-service labs powered by Illumina.
Analyze complex genomic data in novel ways across the entire drug discovery and development process.